ASSOCIATION OF NEUROPEPTIDE S RECEPTOR 1 AND GLUTAMATE DECARBOXYLASE 1 GENE POLYMORPHISMS WITH POSTTRAUMATIC STRESS DISORDER

Shpend Haxhibeqiri1, Valdete Haxhibeqiri2, Ferid Agani3, Aferdita Goci Uka4, Blerina Hoxha4, Alma Dzugub Kulenovic, Abdulah Kućukanlić, Esmina Avdibegović6, Osman Sinanović6, Dragan Babić5, Miro Jakovljević7, Sabina Kučukanlić7, Alma Bravo Mehmedbašić5, Nermina Kravić6, Mirnesa Muminović-Umihan6, Romana Babić7, Marko Pavlović7, Renad Jakšić8, Branka Aukst Marjetić9, Duško Rudan8, Elma Ferić Bojić10, Damir Marjanović10, Christiane Ziegler11, Christiane Wolf12, Bodo Warrings12, Katharina Domschke11 & Jürgen Deckert12

1Institute of Kosovo Forensic Psychiatry, University Clinical Centre of Kosovo, Prishtina, Kosovo
2Department of Clinical Biochemistry, University Clinical Centre of Kosovo, Prishtina, Kosovo
3Faculty of Medicine, University Hasan Prishtina, Prishtina, Kosovo
4Department of Psychiatry, University Clinical Centre of Kosovo, Prishtina, Kosovo
5Department of Psychiatric, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina
6Department of Psychiatry, University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina
7Department of Psychiatry, University Clinical Centre of Mostar, Mostar, Bosnia and Herzegovina
8Department of Psychiatry, University Hospital Centre Zagreb, Zagreb, Croatia
9Department of Psychiatry, University Hospital Centre Sestre Milosrdnice, Zagreb, Croatia
10Department of Genetics and Bioengineering International Burch University, Sarajevo, Bosnia and Herzegovina
11Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
12Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany

received: 4.2.2019; revised: 10.5.2019; accepted: 22.5.2019

SUMMARY

Background: Posttraumatic stress disorder (PTSD) is an anxiety disorder caused by highly traumatic experiences. The aim of this study was to investigate the influence of single nucleotide polymorphisms (SNPs) in the neuropeptide S receptor 1 (NPSR1) and the glutamate decarboxylase 1 (GAD1) gene on PTSD and its psychopathological aspects among individuals affected by the Balkan wars during the 90s.

Subjects and methods: This study was conducted as part of the South Eastern Europe (SEE) study on molecular mechanisms of PTSD. It comprised 719 participants (539 males), including those with current PTSD, remitted PTSD and healthy volunteers. Psychometric evaluation was performed using the Mini International Neuropsychiatric Interview (M.I.N.I.), the Clinician Administered PTSD Scale (CAPS) and the Brief Symptom Inventory (BSI). We examined NPSR1 single nucleotide polymorphism (SNP) rs324981 and GAD1 variant rs3749034 genotypes. Case-control analyses were carried out using logistical regression to determine genotype differences between all patients that had either current or remitted PTSD and control individuals. To analyse the influence of the analysed SNPs on PTSD severity, we performed linear regression analyses with CAPS and BSI within each of the two patient groups separately. All of the calculations were performed for additive allelic, recessive, dominant and genotypic models.

Results: We observed a nominally significant association for the major allele (G) of GAD1 rs3749034 with an increased risk to develop PTSD in a case control analysis in the recessive model (P=0.0315, odds ratio=0.47, SE=0.35). In contrast, a nominally significant association of the minor allele (A) with higher CAPS scores was identified within the patient group with lifetime PTSD in the dominant model (P=0.0372, β=6.29, SE=2.99). None of these results did withstand correction for multiple tests. No nominal significant results of GAD1 rs3749034 were found with regard to the intensity of psychological BSI symptoms. Case-control analyses of NPSR1 rs324981 revealed a nominally significant higher risk for homozygous T allele carriers to develop PTSD (P=0.0452) in the recessive model. On the other hand, the T allele showed a nominally significant association with higher BSI scores in patients suffering from lifetime PTSD in the recessive model (P=0.0434). Again, these results were not significant anymore after correction for multiple tests. No associations of NPSR1 rs324981 and CAPS score was identified.

Conclusion: The findings of this study provide some evidence that the NPSR1 and GAD1 polymorphisms might play a role in the development of war-related PTSD and its related psychological expressions. Further research is needed to elucidate the interactions of specific gene variants and environmental factors in the development of PTSD.

Key words: PTSD - NPSR1 - GAD1 - gene polymorphism - war trauma
INTRODUCTION

Posttraumatic stress disorder (PTSD) occurs in individuals exposed to traumatic events (e.g., life-threatening accidents, rape, military combat), and includes four groups of symptoms: intrusive re-experiencing of trauma, avoidance of stimuli associated with the trauma, negative cognitions and mood associated with the trauma, and excessive psychophysiological reactivity (American Psychiatric Association 2013). The etiology of PTSD is complex and multifactorial, with an interaction between various environmental and genetics factors (Breslau & Kessler 2001, Domschke 2012, Jakovljević 2012).

Chronic PTSD is linked to considerable comorbidity, mortality, and disability during daily activities (Brunello et al. 2001, Gillespie et al. 2009, Weiss et al. 2011). While 50-85% of Americans experience a traumatic event during their lifetime, only a minority of these individuals (5-7%) develop PTSD (Kessler & Wang 2008). Twin studies related to PTSD have addressed the complex genetic relationship between exposure to trauma and disorder risk. Over the last years, there has been an increased interest in identifying genes that increase the risk for PTSD or predict treatment outcome (Sheerin et al. 2017). Because of the phenotypic heterogeneity and complexity of defining PTSD for the purposes of genetic studies, many analyses rely on intermediate phenotypes (Meyer-Lindenberg & Weinberger 2006) or endophenotypes (Gottesman & Gould 2003), which are conceptualized as being more directly related to relevant gene action.

Dysfunction of the gamma-aminobutyric (GABA) system has been proposed as a major neurobiological pathomechanism of anxiety, including PTSD (Domschke & Zwanzger 2008, Nemeroff 2003, Roy-Byrne 2005, Zwanzger & Rupprecht 2005). The key enzyme for the synthesis of the inhibitory and anxiolytic neurotransmitter gamma-aminobutyric acid (GABA), is supposed to influence various mental disorders, including mood and anxiety disorders. Genetic variants of glutamate decarboxylase 1 (GAD1) have been linked to mood symptoms (Lundorf et al. 2005) and panic disorder (Weber et al. 2012). For example, Weber et al. (2012) found an association between GAD1 single nucleotide polymorphisms (SNPs) and panic disorder symptoms, although only among female participants. Similar findings were obtained in a mixed anxiety (including panic disorder) and mood disorder sample (Hettema et al. 2006). With regard to PTSD, only one recent preliminary study documented a significant association between GAD1 polymorphisms and more pronounced PTSD symptoms among American combat veterans (Bountress et al. 2017). However, this preliminary work was based on the genetic risk sum score (GRSS), so no information is available for individual SNPs.

Neuropeptide S receptor 1 (NPSR1) encodes a member of the vasopressin/oxytocin subfamily of G protein-coupled receptors. The encoded membrane protein acts as a receptor for neuropeptide S and affects a variety of cellular processes through its signaling. Based on previous animal and molecular genetic studies, neuropeptide S has been suggested to play a crucial role in the pathogenesis of stress, arousal and anxiety (Vitale et al. 2008, Xu et al. 2004). Moreover, Domschke et al. (2011) have shown an association of the T allele of the NPSR1 SNP rs324981 with panic disorder among female patients, as well as with elevated anxiety sensitivity and increased heart rate during a behavioral avoidance test. In addition, NPSR1 genotypes also influence explicit anxiety ratings through their interaction with stressful life events (Glotzbach-Schoon et al. 2013). Thus, previous research suggests that the T allele of the NPSR1 SNP rs324981 (Domschke et al. 2011, Pape et al. 2010, Raczka et al. 2010) represents a vulnerability factor for the development of anxiety disorders, presumably as a result of facilitated fear conditioning (Mineka & Oehlberg 2008, Orr et al. 2000). However, no studies have been carried out on combat veterans suffering from PTSD.

Given the literature on the involvement of common genetic variants of GAD1 and NPSR1 in stress-related and anxiety disorders, the general aim of this research was to investigate the influence of GAD1 and NPSR1 SNPs on combat-related PTSD, its psychopathological aspects and related coping strategies.

SUBJECTS AND METHODS

Subjects

This research was conducted as part of the South Eastern Europe (SEE)-PTSD study on “Molecular mechanisms of posttraumatic stress disorder” (see Dzubur Kulenović et al. 2016). The study was carried out at five psychiatric research centres in Bosnia and Herzegovina (Sarajevo, Mostar, Tuzla), Croatia (Zagreb), and the Republic of Kosovo (Pristina). These are countries whose population has experienced severe war-related trauma between 1991 and 1999. Recruitment of patients and controls began in 2013 and was completed by the end of 2015. The general inclusion criteria were that participants were at the time of traumatization at least 16 years of age and not older than 65 years at time of recruitment. The exclusion of subjects who survived trauma in childhood was based on the frequently described difference in both clinical presentation and course of PTSD and other psychiatric disorders occurring after trauma exposure at young age (Nemeroff 2016). Other exclusion criteria were: the presence of organic depression, epilepsy, psychotic symptoms, addiction (except smoking), intellectual disability, oncological disorders, valproïd acid use and 1st and 2nd degree relation to an already recruited person.

Of 747 recruited individuals, finally 719 participants (mean age 49.4±7.9; 487 males) could be included in this study. Of those 218 participants (mean age 50.1±6.7;
157 males) suffered from current PTSD, 151 participants had lifetime PTSD (mean age 49.5±8.2; 98 males) and 350 healthy volunteers showed no diagnosable PTSD (mean age 48.8±8.5; 232 males) symptoms. Additional details about the study design, recruitment, gender distribution, methodology of blood collection and procedures of storing and transporting were described in our previous paper (Džubur Kulenović et al. 2016).

Ethical Votes

Ethical votes were obtained at each of the participating clinical center and participants gave their written informed consent according to the principles of the Helsinki declaration (WMA 2013).

Psychometric methods

Interviews were performed by trained medical personnel (psychiatrists, clinical psychologists or psychiatric residents). The presence or absence of PTSD symptoms in the screening stage was assessed using a structured clinical interview - Mini International Neuropsychiatric Interview (M.I.N.I.). The Clinician Administered PTSD Scale (CAPS) (Blake et al. 1996) was performed to make a categorical PTSD diagnosis (current or remitted PTSD) and to assess the severity of PTSD symptoms. And finally the Brief Symptom Inventory (BSI) (Derogatis & Melisaratos 1983) was applied to provide information on the severity of general psychiatric symptoms.

Molecular Analyses

For genotyping, genomic DNA was isolated from frozen venous blood by using the FlexiGene DNA Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions and stored until use at the Laboratory of the Department of Psychiatry, Psychosomatics and Psychotherapy in Würzburg, at -80°C. The GAD1 SNP rs3749034 was genotyped by means of a custom designed KASP genotyping assay (LGC, Berlin, Germany). PCR reaction including an end-point fluorescent readout was performed according to manufacturers’ instructions in a CFX384 Touch Cycler (Biorad, Munich, Germany). Genotypes were determined by using the CFX Manager Software. The functional variant NPSR1 rs324981 was genotyped according to already published protocols (see Domschke et al. 2011).

Statistical analyses

Statistical analyses were performed using PLINK 1.9. Both variants GAD1 rs3749034 and NPSR1 rs324981 were polymorphous (minor allele frequency >20%), reached a minimal genotyping call rate of 96% and did not deviate from Hardy-Weinberg equilibrium (p>0.05 after Bonferroni correction). Logistic regression was used for case-control analyses in which both patient groups were analyzed jointly versus the control individuals. Within the two groups of patients, i.e. individuals with current or lifetime PTSD, linear regression was carried out for the dimensional CAPS and BSI scores, respectively. The following models were tested in all phenotypes: additive allelic, dominant and recessive, as well as the genotypic model. The significance level was Bonferroni adjusted for 23 variants that were analyzed in total in the entire project (α=0.002) as already described by Džubur Kulenović et al. (2016). The level of significance was set at P≤0.05 (two-tailed) for all the analyses.

RESULTS

In this study we investigated first in a case-control approach (N=719) the role of the two known polymorphisms GAD1 rs3749034 and NPSR1 rs324981, on the development of a PTSD and characterized in a second step the influence of allelic variation on PTSD linked CAPS and BSI total scores individually in all cases who suffered either from current PTSD (N=211 for GAD1 and 215 for NPSR1) or lifetime PTSD (N=148 for GAD1 and 150 for NPSR1) symptoms.

GAD1 rs3749034 polymorphism

Categorical analyses of GAD1 rs3749034 reached nominal significance in the recessive model (P=0.0315, odds ratio =0.47, SE=0.35) (Table 1) with the major allele (G) representing the risk allele. With regard to the CAPS phenotype we obtained not in the current, but in the lifetime PTSD group a nominal association in the dominant model (P=0.0372, β=6.29, SE=2.99) (Table 1 and Figure 1), where carriers of the minor (A) allele was used for case-control analyses in which both patient groups were analyzed jointly versus the control individuals. Within the two groups of patients, i.e. individuals with current or lifetime PTSD, linear regression was carried out for the dimensional CAPS and BSI scores, respectively. The following models were tested in all phenotypes: additive allelic, dominant and recessive, as well as the genotypic model. The significance level was Bonferroni adjusted for 23 variants that were analyzed in total in the entire project (α=0.002) as already described by Džubur Kulenović et al. (2016). The level of significance was set at P≤0.05 (two-tailed) for all the analyses.

RESULTS

In this study we investigated first in a case-control approach (N=719) the role of the two known polymorphisms GAD1 rs3749034 and NPSR1 rs324981, on the development of a PTSD and characterized in a second step the influence of allelic variation on PTSD linked CAPS and BSI total scores individually in all cases who suffered either from current PTSD (N=211 for GAD1 and 215 for NPSR1) or lifetime PTSD (N=148 for GAD1 and 150 for NPSR1) symptoms.

GAD1 rs3749034 polymorphism

Categorical analyses of GAD1 rs3749034 reached nominal significance in the recessive model (P=0.0315, odds ratio =0.47, SE=0.35) (Table 1) with the major allele (G) representing the risk allele. With regard to the CAPS phenotype we obtained not in the current, but in the lifetime PTSD group a nominal association in the dominant model (P=0.0372, β=6.29, SE=2.99) (Table 1 and Figure 1), where carriers of the minor (A) allele was used for case-control analyses in which both patient groups were analyzed jointly versus the control individuals. Within the two groups of patients, i.e. individuals with current or lifetime PTSD, linear regression was carried out for the dimensional CAPS and BSI scores, respectively. The following models were tested in all phenotypes: additive allelic, dominant and recessive, as well as the genotypic model. The significance level was Bonferroni adjusted for 23 variants that were analyzed in total in the entire project (α=0.002) as already described by Džubur Kulenović et al. (2016). The level of significance was set at P≤0.05 (two-tailed) for all the analyses.

RESULTS

In this study we investigated first in a case-control approach (N=719) the role of the two known polymorphisms GAD1 rs3749034 and NPSR1 rs324981, on the development of a PTSD and characterized in a second step the influence of allelic variation on PTSD linked CAPS and BSI total scores individually in all cases who suffered either from current PTSD (N=211 for GAD1 and 215 for NPSR1) or lifetime PTSD (N=148 for GAD1 and 150 for NPSR1) symptoms.

GAD1 rs3749034 polymorphism

Categorical analyses of GAD1 rs3749034 reached nominal significance in the recessive model (P=0.0315, odds ratio =0.47, SE=0.35) (Table 1) with the major allele (G) representing the risk allele. With regard to the CAPS phenotype we obtained not in the current, but in the lifetime PTSD group a nominal association in the dominant model (P=0.0372, β=6.29, SE=2.99) (Table 1 and Figure 1), where carriers of the minor (A) allele was used for case-control analyses in which both patient groups were analyzed jointly versus the control individuals. Within the two groups of patients, i.e. individuals with current or lifetime PTSD, linear regression was carried out for the dimensional CAPS and BSI scores, respectively. The following models were tested in all phenotypes: additive allelic, dominant and recessive, as well as the genotypic model. The significance level was Bonferroni adjusted for 23 variants that were analyzed in total in the entire project (α=0.002) as already described by Džubur Kulenović et al. (2016). The level of significance was set at P≤0.05 (two-tailed) for all the analyses.
Table 1. Association results of GAD1 rs3749034, along with genotype- and allele counts, for individuals in analysis, CAPS and BSI means and standard deviations (SD), as well as nominal p-values of regression analyses

| Allelic Model | Genotypic Model | Dominant Model | Recessive Model |
|---------------|----------------|----------------|----------------|----------------|
| GAD1 rs3749034|                |                |                |                |
| A             | G             | AA             | AG             | GG             |
| 153           | 523           | 25             | 103            | 210            |
| PTSDlifetime  | 57            | 239            | 5              | 47             |
| PTSDcurrent   | 77            | 345            | 8              | 61             |
| Pcase-control-value | 0.0778 | 0.0889 | 0.2516 | 0.0315 |
| CAPSlifetime (mean±SD) | 70.7±19.1 | 66.0±17.1 | 64.4±14.5 | 72.1±19.7 |
| CAPScurrent (mean±SD) | 80.5±23.8 | 79.0±20.1 | 85.5±26.2 | 79.2±23.0 |
| Pcase-value | 0.0945 | 0.0703 | 0.0372 | 0.7063 |
| BSIlifetime (mean±SD) | 66.9±43.2 | 75.0±50.6 | 42.8±10.8 | 72.3±45.8 |
| PBSI-value | 0.5823 | 0.6932 | 0.7621 | 0.3931 |
| BSIcurrent (mean±SD) | 112.6±49.0 | 112.7±45.5 | 103.8±52.6 | 115.1±47.7 |
| PBSI-value | 0.2579 | 0.3295 | 0.4454 | 0.1529 |

GAD1 - glutamate decarboxylase 1; PTSD - posttraumatic stress disorder; CAPS - Clinician Administered PTSD Scale; BSI - Brief Symptom Inventory; Italics indicates p<0.05

Table 2. Association results of NPSR1 rs324981, along with genotype- and allele counts, for individuals in analysis, CAPS and BSI means and standard deviations (SD), as well as nominal P-values of regression analyses

| Allelic Model | Genotypic Model | Dominant Model | Recessive Model |
|---------------|----------------|----------------|----------------|
| NPSR1 rs324981|                |                |                |                |
| T             | A             | TT             | TA             | AA             |
| 331           | 357           | 72             | 187            | 85             |
| PTSDlifetime  | 155           | 145            | 40             | 75             |
| PTSDcurrent   | 218           | 212            | 60             | 98             |
| Pcase-control-value | 0.2577 | 0.0935 | 0.8787 | 0.0452 |
| CAPSlifetime (mean±SD) | 66.8±17.8 | 67.0±17.4 | 65.9±14.6 | 68.1±19.9 |
| CAPScurrent (mean±SD) | 78.1±21.0 | 80.4±20.7 | 77.6±22.8 | 78.7±18.6 |
| Pcase-value | 0.9060 | 0.6968 | 0.5499 | 0.7054 |
| BSIlifetime (mean±SD) | 77.8±50.6 | 68.7±47.7 | 87.0±50.5 | 67.4±48.8 |
| PBSI-value | 0.2511 | 0.4758 | 0.2389 | 0.4669 |
| BSIcurrent (mean±SD) | 113.4±45.9 | 112.3±46.5 | 114.4±45.7 | 112.2±46.1 |
| PBSI-value | 0.1198 | 0.1246 | 0.6132 | 0.0434 |
| PBSI-value | 0.8728 | 0.9614 | 0.7944 | 0.9986 |

NPSR1 - neuropeptide S receptor 1; PTSD - posttraumatic stress disorder; CAPS - Clinician Administered PTSD Scale; BSI - Brief Symptom Inventory; Italics indicates p<0.05

showed nominal significantly higher average CAPS scores than others. Neither in the current nor in the lifetime PTSD sample significant differences between the genotypes with regard to the intensity of psychological BSI symptoms were identified (Pall>0.1) (Table 1).

NPSR1 rs324981 polymorphism

Case-control analyses of NPSR1 rs324981 revealed in the recessive model a nominally significant higher risk for homozygous T allele carriers to develop PTSD (P=0.0452) (Table 2). Within the other models no impact on the categorical phenotype of PTSD was detectable (P>0.05) (Table 2). When tests where run for the dimensional CAPS and BSI total scores, a nominally significant association was found for BSI in patients suffering from lifetime PTSD (recessive model: P=0.0434, 18.70, SE=9.17) (Table 2), with the T allele conveying genetic risk. However, results for the BSI questionnaire could not be replicated in patients with diagnosed current PTSD (P=0.05) (Table 2). Analyses on CAPS total scores revealed neither for the current nor for the lifetime PTSD group any association (P=0.05) (Table 2).

DISCUSSION

To the best of our knowledge, this multicenter study was the first to assess the associations of the GAD1 rs3749034 and NPSR1 rs324981 polymorphisms with war-related PTSD and its accompanying psychological disturbances among the population of the Balkan war survivors. There were found nominal significant differences in the risk of PTSD development in the overall recessive model for the GAD1 rs3749034 polymorphism. With regard to the CAPS phenotype in the lifetime PTSD group, we obtained a significant result in the dominant model. With regard to PTSD, only one recent preliminary study documented a significant association between GAD1 polymorphisms and more pronounced PTSD symptoms among American combat veterans.
examine additional SNPs in genes involved in the regulation of war-related PTSD. It will be of interest to evidence that NPSR1 and GAD1 polymorphisms might

CONCLUSION

In conclusion, the results of this study provide some evidence that NPSR1 and GAD1 polymorphisms might play a role in the development and symptomatic expression of war-related PTSD. It will be of interest to examine additional SNPs in genes involved in the regulation of NPSR1 and GAD1 expression. As specific genes can facilitate the occurrence of certain psychiatric disorders, including war-related PTSD, the findings of this study could further inform our understanding of the complex pathophysiology of PTSD in the framework of the stress-diathesis or vulnerability-resilience model (Jakovljevic et al. 2012, 2017).

Acknowledgements:

We thank all the participants and their families without whose idealistic and enthusiastic support the study would not have been possible. We also would like to thank at Sarajevo: the Association of Women Victims of War and Bakira Hasècic, the Association of Physically Handicapped, Zilko Buljić, Zoran Budimlija, MD, PhD, Jasminka Krehic, MD, PhD, Elvira Saba

Conflict of interest: None to declare.

References

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Arlington, VA, APA, 2013

2. Amstadter AB, Koenen KC, Ruggiero KJ, Acierno R, Galea S, Kilpatrick DG et al: Variant in RGS2 moderates posttraumatic stress symptoms following potentially traumatic event exposure. J Anxiety Disord 2009; 23:369–373

3. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS & Keane TM: The development of a clinician-administered PTSD scale. J Trauma Stress 1995; 8:75-90

4. Bountress K, Sheerin C, Amstadter AB, Mandel H, Voltin J & Wang Z: The relation between GAD1 and PTSD symptoms: Shared risk for depressive symptoms. Psychiatry Res 2017; 258:607-608
5. Brunello N, Davidson JR, Deahl M, Kessler RC, Mendlewicz J, Racagni G et al.: Post-traumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology 2001; 43:150–162

6. Breslau N & Kessler RC: The stressor criterion in DSM-IV, posttraumatic stress disorder: An empirical investigation. Biol Psychiatry 2001; 50:699–704

7. Canti T & Lesch KP: Long story short: the serotonin transporter in emotion regulation and social cognition. Nat Neurosci 2007; 10:1103–1109

8. Cornelis MC, Nugent NR, Amstadter AB, & Koenen KC: Genetics of post-traumatic stress disorder: Review and recommendations for genome-wide association studies. Curr Psychiatry Rep 2010; 12:313-326

9. Derogatis L & Melisaratos N: The Brief Symptom Inventory: A introductory report. Psychol Med 1983; 13:593-605

10. Domshche K & Zwangner P: GABAergic and endocannabinoid dysfunction in anxiety - future therapeutic targets? Curr Pharm Des 2008; 14:5308–17

11. Domshche K, Reif A, Weber H, Richter J, Hohoff C, Ohrmann P et al: Neuropeptide S receptor gene - converging evidence for a role in panic disorder. Mol Psychiatry 2011; 16:938–948

12. Domshche K: Patho-genetics of posttraumatic stress disorder. Psychiatr Danub 2012; 2:367-273

13. Donner J, Sipila T, Ripatti S, Kananen L, Chen X et al.: Patho-genetics of posttraumatic stress disorder. Biol Psychiatry 2011; 16:938–948

14. Gillespie CF, Phifer J, Bradley B, & Ressler KJ: Risk and resilience: genetic and environmental influences on development of the stress response. Depress Anxiety 2009; 26:984–992

15. Gillespie CF, Phifer J, Bradley B & Ressler KJ: Risk and resilience: genetic and environmental influences on development of the stress response. Depress Anxiety 2009; 26:984–992

16. Goddard AW, Mason GF, Appel M, Rothman DL, Gueorguieva R, Behar KL et al.: Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry 2004; 161:2186–93

17. Goenjian AK, Bailey JN, Walling DP, Steinberg AM, Schindlmeier P, Baumann C et al.: Contextual fear conditioning in virtual reality is affected by 5HTTLPR and NPSR1 polymorphisms: effects on fear-potentiated startle. Front Behav Neurosci 2013; 7:31

18. Ham BJ, Sang Y, Kim N, Kim SI, Kim JE, Kim DJ et al.: Decreased GABA levels in anterior cingulate and basal ganglia in medicated subjects with panic disorder: a proton magnetic resonance spectroscopy (1H-MRS) study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:403–11

19. Heike Weber et al.: Gender Differences in Associations of Glutamate Decarboxylase 1 Gene (GAD1) Variants with Panic Disorder. PLoS One 2012; 7:e37651

20. Hettema JM, An SS, Neale MC, Bukkszar J, van den Oord EJ, Kendler KS et al.: Association between glutamic acid decarboxylase genes and anxiety disorders, major depression, and neuroticism. Mol Psychiatry 2006; 11:752–762

21. Howe AS, Buttenschon HN, Buni-Fatemi A, Maron E, Owoda T, Erhardt A et al.: Candidate genes in panic disorder: meta-analyses of 23 common variants in major anxiogenic pathways. Mol Psychiatry 2016; 21: 665–679

22. Jakovljevic M, Brijakovc L, Jakasic N, Loncar M, Aukst-Margetic B & Lasic D: Posttraumatic stress disorder (PTSD) from different perspectives: a transdisciplinary integrative approach. Psychiatr Danub 2017; 29:238-244

23. Kessler RC & Wang PS: The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health 2008; 29:115–129

24. Koenen KC, Moffitt TE, Caspi A, Gregory A, Harrington H & Poulton R: The Developmental Mental-Disorder Histories of Adults With Posttraumatic Stress Disorder: A Prospective Longitudinal Birth Cohort Study. J Abnorm Psychol 2008; 117:460–466

25. Koenen KC, Duncan LE, Liberzon I & Ressler KJ: From candidate genes to genome-wide association: The challenges and promise of posttraumatic stress disorder genetic studies. Biol Psychiatry 2013; 74:634-636

26. Lappalainen J, Sanacora G, Kranzler HR, Malison R, Hibbard ES, Price LH et al.: Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. Am J Med Genet 2004; 124B:81–86

27. Leon-Feldner EW, Feldner MT, Knapp A, Bunaciu L, Blumenthal H & Amstadter AB: Offspring psychological and biological correlates of parental posttraumatic stress: review of the literature and research agenda. Clin Psychol Rev 2013; 33:1106–1133

28. Lundorf MD et al.: Mutational screening and association study of glutamate decarboxylase 1 as a candidate susceptibility gene for bipolar affective disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2005; 135B:94–101

29. Meyer-Lindenberg A & Weinberger DR: Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 2006; 7:818–827

30. Mineka S & Oehlberg K: The relevance of recent developments in classical conditioning to understanding the etiology and maintenance of anxiety disorders. Acta Psychol 2008; 127:567–580
37. Marenco S, Savostyanova AA, van der Veen JW, Geramita M, Stern A et al.: Genetic modulation of GABA levels in the anterior cingulate cortex by GAD1 and COMT. Neuropsychopharmacology 2010; 35:1708–1717
38. Nemeroﬀ CB: The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 2003; 37:133–146
39. Orr SP, Metzger LJ, Lasko NB, Macklin ML, Peri T & Pitman RK: De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. J Abnorm Psychol 2000; 109:290–298
40. Okamura N, Hashimoto K, Iyo M, Shimizu E, Dempfe A, Friedel S & Reinscheid RK: Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deﬁcit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1444–1448
41. Roy-Byrne PP: The GABA-benzodiazepine receptor complex: structure, function, and role in anxiety. J Clin Psychiatry 2005; 66:14–20
42. Roy-Byrne PP, Cowley DS, Hommer D, Greenblatt DJ, Kramer GL & Petty F: Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls. Psychopharmacology (Berl) 1992; 109:153–156
43. Raczka KA, Gartmann N, Mechias ML, Reif A, Büchel C, Deckert J et al.: A neuropeptide S receptor variant associated with overinterpretation of fear reactions: a potential neurogenetic basis for catastrophizing. Mol Psychiatry 2010; 15:1067–1074
44. Pape HC, Jüngling K, Seidenbecher T, Lesting J & Reinscheid RK: Neuropeptide S: a transmitter system in the brain regulating fear and anxiety. Neuropsychopharmacology 2010; 35:29–34
45. Sheerin CM, Lind MJ, Bountress KE, Nugent NR & Amstadter AB: The genetics and epigenetics of PTSD: overview, recent advances, and future directions. Curr Opin Psychol 2017; 14:5-11
46. Vitale G, Filaferro M, Ruggieri V, Pennella S, Frigeri C, Rizzi A et al.: Anxiolytic-like effect of neuropeptide S in the rat defensive burying. Peptides 2008; 29:2286–2291
47. Weber H, Scholz CJ, Domschke K, Baumann C, Klauke B, Jacob CP et al.: Gender differences in associations of glutamate decarboxylase 1 gene (GAD1) variants with panic disorder. PLoS One 2012; 7:37651
48. Weiss T, Skelton K, Phifer J, Jovanovic T, Gillespie CF, Smith A, Umpeirerez G, Bradley B & Ressler KJ. Post-traumatic stress disorder is a risk factor for metabolic syndrome in an impoverished urban population. Gen Hosp Psychiatry 2011; 33:135–142
49. Weiss T, Skelton K, Phifer J, Jovanovic T, Gillespie CF, Smith A et al.: Post-traumatic stress disorder is a risk factor for metabolic syndrome in an impoverished urban population. Gen Hosp Psychiatry 2011; 33:135–142
50. Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH et al.: Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 2004; 43:487–497
51. Zwanzger P & Rupprecht: Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci 2005; 30:167–175